Clinical Trial

IBRX-042 In Participants With HPV-Associated Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-07-26; most recent amendment 2025-10-16.
Status change: Recruiting → Active, Not Recruiting 2025-10-16
Status change: Not Yet Recruiting → Recruiting 2024-06-20
Trial Details
NCT Number NCT05976828
Lead Sponsor ImmunityBio, Inc.
Conditions HPV-Related Carcinoma
Enrollment 12 participants
Start Date 2024-06-14
Primary Completion 2027-09-02 (estimated)
Study Completion 2033-08-14 (estimated)
Updated on ClinicalTrials.gov 2025-10-20